Longevity Competitors

Stocks . USA . 
Stock . Longevity Health Holdings,
XAGE Stock   0.44  0.01  2.22%   
Longevity Health Hol competes with Celularity, ZyVersa Therapeutics, Concord Medical, Aditxt, and INVO Fertility,; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Longevity Health competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Longevity Health to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Longevity Health Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Longevity Health competition on your existing holdings.
  
Build AI portfolio with Longevity Stock
At present, Longevity Health's Return On Equity is projected to increase slightly based on the last few years of reporting. At present, Longevity Health's Intangible Assets are projected to decrease significantly based on the last few years of reporting. The current year's Intangibles To Total Assets is expected to grow to 0.01, whereas Non Currrent Assets Other are forecasted to decline to (148.1 M).
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.020.4512.46
Details
Intrinsic
Valuation
LowRealHigh
0.020.4412.45
Details
Naive
Forecast
LowNextHigh
0.010.4912.50
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.330.530.73
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Longevity Health. Your research has to be compared to or analyzed against Longevity Health's peers to derive any actionable benefits. When done correctly, Longevity Health's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Longevity Health Hol.

Longevity Health Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Longevity Health and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Longevity and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Longevity Health Hol does not affect the price movement of the other competitor.

High positive correlations

SISI
+ 0.86
ADTX
IVF
+ 0.84
CCM
ADTX
+ 0.79
CCM
IVF
+ 0.79
ADTX
SCNI
+ 0.78
CELU
LIXT
+ 0.78
SISI
  

High negative correlations

SYRA
- 0.04
SCNI

Risk-Adjusted Indicators

There is a big difference between Longevity Stock performing well and Longevity Health Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Longevity Health's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

Cross Equities Net Income Analysis

Compare Longevity Health Hol and related stocks such as Celularity, ZyVersa Therapeutics, and Concord Medical Services Net Income Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Shareholders Equity Per ShareDebt To Equity
Capex Per ShareGraham Net Net
Average ReceivablesRevenue Per Share
Interest Debt Per ShareDebt To Assets
Enterprise Value Over E B I T D AShort Term Coverage Ratios
Price Earnings RatioOperating Cycle
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationReturn On Capital Employed
Debt Equity RatioEbit Per Revenue
Quick RatioDividend Paid And Capex Coverage Ratio
Net Income Per E B TCash Ratio
Cash Conversion CycleOperating Cash Flow Sales Ratio
Days Of Inventory OutstandingDays Of Sales Outstanding
Free Cash Flow Operating Cash Flow RatioCash Flow Coverage Ratios
Price To Book RatioFixed Asset Turnover
Capital Expenditure Coverage RatioPrice Cash Flow Ratio
Enterprise Value MultipleDebt Ratio
Cash Flow To Debt RatioPrice Sales Ratio
Return On AssetsAsset Turnover
Net Profit MarginGross Profit Margin
Price Fair ValueReturn On Equity
2010201120122013201420152016201720182019202020212022202320242025

Longevity Health Hol and related stocks such as Celularity, ZyVersa Therapeutics, and Concord Medical Services Net Income description

Net income is one of the most important fundamental items in finance. It plays a large role in Longevity Health Hol financial statement analysis. It represents the amount of money remaining after all of Longevity Health Holdings, operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Longevity Health Competitive Analysis

The better you understand Longevity Health competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Longevity Health's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Longevity Health's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
XAGE CELU ZVSA CCM ADTX IVF SISI LIXT SCNI SYRA
 2.22 
 0.44 
Longevity
 1.52 
 1.34 
Celularity
 7.14 
 0.13 
ZyVersa
 4.33 
 3.76 
Concord
 1.75 
 1.12 
Aditxt
 3.45 
 0.84 
INVO
 13.64 
 0.19 
Shineco
 0.49 
 4.07 
Lixte
 6.67 
 0.70 
Scinai
 9.09 
 0.10 
Syra
Market Volatility
(90 Days Market Risk)
Out of control
Dangerous
Risky
Very risky
Relatively risky
Out of control
Out of control
Unstable
Very steady
Out of control
Market Performance
(90 Days Performance)
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Soft
Odds of Financial Distress
(Probability Of Bankruptcy)
Risky
Risky
High
Strong
Risky
Risky
Risky
Risky
Risky
Risky
Current Valuation
(Equity Enterprise Value)
Fairly Valued
Under Valued
Under Valued
Fairly Valued
Under Valued
Over Valued
Fairly Valued
Over Valued
Under Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Sell
Sell
Strong Sell
Strong Sell
Strong Sell
Cautious Hold
Strong Sell
Hold
Current Ratio
N/A
0.91
N/A
0.71
0.52
N/A
2.06
15.1
0.16
N/A
Net Asset
1.47 M
132.68 M
20.6 M
6.73 B
32.14 M
46.45 M
84.18 M
1.15 M
13.45 M
3.68 M
Profit Margin
N/A
-1.99
N/A
-0.45
N/A
N/A
N/A
N/A
4.48
-0.17
EBITDA
(10.5 M)
(43.71 M)
(9.14 B)
(345.62 M)
(27.04 M)
(7.14 M)
(12.08 M)
(3.57 M)
(6.99 M)
(3.68 M)
Operating Margin
-2.95
-2.43
N/A
-0.72
N/A
-1.5
-91.79
N/A
-4.87
-0.14
Current Valuation
5.14 M
104.23 M
(2.04 M)
535.65 M
7.54 M
43.84 M
11.81 M
29.62 M
9.6 M
(550.28 K)
Price To Book
N/A
9.89
0.21
3.0
0.29
5.97
0.0111
13.74
1.17
0.54
Retained Earnings
(68.87 M)
(899.68 M)
(112.63 M)
(4.37 B)
(168.09 M)
(67.16 M)
(54.34 M)
(52.07 M)
(117.54 M)
(8.82 M)
Current Asset
N/A
N/A
N/A
1.51 B
N/A
N/A
N/A
1.38 M
143 K
N/A
Beta
0.56
0.78
0.82
-1.16
1.29
N/A
-1.33
0.89
1.67
4.53
Number Of Employees
15
123
7
595
26
33
119
2
31
57
Shares Outstanding
1.48 M
28.48 M
8.1 M
2.82 M
1.78 M
2.16 M
900.61 K
8 M
3.19 M
11.34 M
Cash Flow From Operations
(4.39 M)
(6.4 M)
(7.56 M)
(397.75 M)
(16.76 M)
(2.97 M)
(3.93 M)
(3.16 M)
(6.33 M)
(2.93 M)
Total Debt
638.99 K
68.84 M
12.08 M
3.93 B
6.92 M
9.9 M
29.66 M
318.28 K
2.09 M
452.08 K
Return On Equity
N/A
-63.67
-1.13
-0.29
-2.82
N/A
-0.83
-1.3
0.18
-0.46
Return On Asset
-0.67
-0.25
-0.46
-0.0448
-0.62
N/A
-0.1
-0.68
-0.4
-0.21
Number Of Shares Shorted
8.83 K
381.79 K
359.25 K
905
86.66 K
94.55 K
28.89 K
127.47 K
24.93 K
403.78 K
Book Value Per Share
-3.79
-0.71
-1.45
-72.93
-151.87
-108.71
52.36
0.41
1.47
0.13
Current Liabilities
N/A
N/A
N/A
1.51 B
N/A
N/A
N/A
140 K
907 K
N/A
Total Asset
1.47 M
132.68 M
20.6 M
6.73 B
32.14 M
46.45 M
84.18 M
1.15 M
13.45 M
3.68 M
Short Ratio
0.01
6.41
0.25
0.17
0.04
0.07
0.02
1.4
0.52
1.68
Debt To Equity
N/A
0.41
N/A
1.25
3.21
N/A
0.49
0.16
N/A
N/A
Target Price
N/A
2.5
20.0
1.2
61.0
N/A
N/A
N/A
700.0
1.8
Shares Owned By Institutions
4.93
13.51
5.14
1.36
0.02
5.27
0.085
9.79
4.74
N/A
Market Capitalization
5.92 M
37.59 M
1.08 M
17.06 M
2.02 M
5.51 M
201.74 K
32.41 M
2.39 M
1.19 M
Price To Earning
N/A
3.08
N/A
-3.9
N/A
N/A
N/A
-2.96
N/A
N/A
Price To Sales
10.56
0.93
N/A
0.0467
340.57
0.84
0.021
N/A
2.08
0.16
Net Income
(11.8 M)
(57.89 M)
(9.41 M)
(652.08 M)
(34.45 M)
(9.1 M)
(22.45 M)
(3.59 M)
4.8 M
(3.76 M)
Earnings Per Share
-11.87
-3.33
-3.32
-5.33
-829.58
-105.51
-6802.27
-1.19
4.0
-0.08
Shares Owned By Insiders
13.57
39.57
0.02
17.99
N/A
11.58
51.4
0.93
10.29
34.01
Revenue
50.32 K
54.22 M
N/A
383.96 M
133.99 K
6.53 M
9.8 M
N/A
658 K
7.98 M
Working Capital
(4.92 M)
(33.12 M)
(9.52 M)
(1.14 B)
(21.41 M)
(16.61 M)
(6.66 M)
827.22 K
585 K
2.74 M
Cash And Equivalents
N/A
42.65 M
N/A
157.39 M
803.97 K
N/A
15.33 M
7.74 M
13.45 K
N/A
Cash Per Share
N/A
0.29
N/A
1.72
0.71
N/A
0.94
0.47
N/A
N/A
Gross Profit
313.78 K
20.54 M
N/A
(41.85 M)
(67.53 K)
2.74 M
771.03 K
N/A
(1.69 M)
2.23 M
Day Typical Price
0.44
1.33
0.14
3.8
1.11
0.85
0.19
4.06
0.73
0.11
Accumulation Distribution
N/A
0.0584
0.13
0.11
0.1
0.0787
N/A
0.0386
0.13
0.17
Market Facilitation Index
N/A
0.08
0.02
0.43
0.12
0.07
N/A
0.16
0.1
0.02
Daily Balance Of Power
(9,223,372,036,855)
0.25
(0.50)
(0.40)
(0.17)
(0.43)
(9,223,372,036,855)
0.125
(0.50)
(0.50)
Period Momentum Indicator
(0.01)
0.02
(0.01)
(0.17)
(0.02)
(0.03)
(0.03)
0.02
(0.05)
(0.01)
Rate Of Daily Change
0.98
1.02
0.93
0.96
0.98
0.97
0.86
1.0
0.93
0.91
Day Median Price
0.44
1.33
0.14
3.82
1.11
0.86
0.19
4.06
0.75
0.11
Price Action Indicator
(0.01)
0.02
(0.01)
(0.14)
N/A
(0.03)
(0.01)
0.02
(0.07)
(0.01)
Coefficient Of Variation
(3,919)
(835.95)
8139.4
(774.88)
(240.25)
(670.69)
(932.33)
(1,385)
(1,045)
1741.0
Mean Deviation
8.71
3.61
4.5
4.24
10.72
8.18
13.33
3.03
4.84
8.68
Jensen Alpha
(0.60)
(0.73)
(0.01)
(0.77)
(5.89)
(2.17)
(2.23)
(0.39)
(0.90)
0.6276
Total Risk Alpha
(1.60)
(1.18)
(0.60)
(1.34)
(7.23)
(3.85)
(4.79)
(0.75)
(1.34)
(0.62)
Sortino Ratio
N/A
N/A
(0.001)
N/A
N/A
N/A
N/A
N/A
N/A
0.0519
Downside Variance
N/A
N/A
70.64
N/A
N/A
N/A
N/A
N/A
N/A
140.05
Standard Deviation
11.95
5.17
6.26
5.63
13.79
14.96
22.3
4.1
6.56
12.18
Kurtosis
0.1311
2.29
0.1013
0.7478
0.3269
19.76
3.98
0.9216
2.97
1.76
Potential Upside
22.5
10.29
7.69
8.76
19.39
11.39
40.0
7.16
10.32
21.26
Treynor Ratio
(0.08)
(0.47)
0.0618
(1.63)
(3.10)
2.44
1.08
(0.29)
(0.18)
0.8373
Maximum Drawdown
56.31
26.97
31.93
29.88
63.67
131.99
114.83
21.12
38.82
67.34
Variance
142.74
26.72
39.23
31.7
190.14
223.9
497.39
16.84
43.04
148.34
Market Risk Adjusted Performance
(0.07)
(0.46)
0.0718
(1.62)
(3.09)
2.45
1.09
(0.28)
(0.17)
0.8473
Risk Adjusted Performance
(0.01)
(0.08)
0.0175
(0.08)
(0.28)
(0.1)
(0.07)
(0.04)
(0.06)
0.0497
Skewness
0.2239
0.8551
(0.08)
0.4361
(0.16)
2.91
0.5058
0.3132
(0.86)
0.7485
Semi Deviation
N/A
N/A
5.22
N/A
N/A
N/A
N/A
N/A
N/A
9.56
Information Ratio
(0.03)
(0.14)
(0)
(0.14)
(0.42)
(0.15)
(0.11)
(0.09)
(0.11)
0.0504
Value At Risk
(20.00)
(8.15)
(7.14)
(9.32)
(28.09)
(20.16)
(33.33)
(7.45)
(9.29)
(20.36)
Expected Short fall
N/A
N/A
(7.96)
N/A
N/A
N/A
N/A
N/A
N/A
(10.90)
Downside Deviation
N/A
N/A
8.4
N/A
N/A
N/A
N/A
N/A
N/A
11.83
Semi Variance
N/A
N/A
27.21
N/A
N/A
N/A
N/A
N/A
N/A
91.31

Longevity Health Competition Performance Charts

Five steps to successful analysis of Longevity Health Competition

Longevity Health's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Longevity Health Hol in relation to its competition. Longevity Health's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Longevity Health in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Longevity Health's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Longevity Health Hol, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Longevity Health position

In addition to having Longevity Health in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Driverless Cars Thematic Idea Now

Driverless Cars
Driverless Cars Theme
It encompasses large technology companies, automotive makers, security firms, and thematic ETFs across multiple industries. These entities are directly or indirectly involved in shaping the development and marketing of self-driving vehicles. The Driverless Cars theme has 30 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Driverless Cars Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Longevity Health Hol is a strong investment it is important to analyze Longevity Health's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Longevity Health's future performance. For an informed investment choice regarding Longevity Stock, refer to the following important reports:
How To Invest In Longevity
Details
Is Longevity Stock a good investment?
Details
What is Longevity Health's Net Worth?
Details
Largest Household & Personal Products Companies
View
Largest Consumer Defensive Companies
View
Check out Longevity Health Correlation with its peers.
You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Longevity Health. If investors know Longevity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Longevity Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(11.87)
Revenue Per Share
0.729
Return On Assets
(0.67)
The market value of Longevity Health Hol is measured differently than its book value, which is the value of Longevity that is recorded on the company's balance sheet. Investors also form their own opinion of Longevity Health's value that differs from its market value or its book value, called intrinsic value, which is Longevity Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Longevity Health's market value can be influenced by many factors that don't directly affect Longevity Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Longevity Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Longevity Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Longevity Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY